Chen Yi-He, Lin Hui, Xie Cheng-Long, Hou Jian-Wen, Li Yi-Gang
Department of Cardiology, Xinhua Hospital Affiliated to the Medical School of Shanghai Jiaotong University, 1665 Kongjiang Road, Shanghai 200092, China.
Department of Respiratory, The Second Af?liated Hospital of Wenzhou Medical University, Wenzhou 325027, China.
Europace. 2017 Apr 1;19(4):552-559. doi: 10.1093/europace/euw201.
Adenosine had been reported to unmask dormant conduction and thus identify pulmonary vein at risk of reconnection. However, the role of adjunctive adenosine infusion after pulmonary vein isolation (PVI) on long-term arrhythmia-free survival was still contentious. The purpose of the present meta-analysis was to assess the association of adenosine testing with long-term ablation success in patients with atrial fibrillation (AF) (i.e. freedom from AF recurrence).
We systematically searched the electronic databases and finally included 10 studies, with 1771 patients undergoing adenosine-guided PVI and 1787 patients undergoing conventional PVI. In comparison to conventional PVI alone, adenosine-guided PVI improved the arrhythmia-free survival by 17% during a median follow-up of 12 months [relative risk (RR): 1.17; 95% confidence interval (CI): 1.07 to 1.27; P = 0.014]. Patients undergoing adenosine-guided PVI had similar fluoroscopy time to those who undergoing conventional PVI [weighted mean difference (WMD): 1.76; 95% CI: -5.66 to 9.17; P = 0.64], despite longer procedure time (WMD: 20.6; 95% CI: 0.70 to 40.50; P = 0.042).
From the available data of clinical studies, adenosine-guided PVI was associated with an increased arrhythmia-free survival when compared with conventional PVI in patients undergoing catheter ablation for AF.
据报道,腺苷可揭示隐匿性传导,从而识别有重新连接风险的肺静脉。然而,肺静脉隔离(PVI)后辅助输注腺苷对长期无心律失常生存的作用仍存在争议。本荟萃分析的目的是评估腺苷检测与心房颤动(AF)患者长期消融成功(即无AF复发)之间的关联。
我们系统检索了电子数据库,最终纳入10项研究,其中1771例患者接受腺苷引导的PVI,1787例患者接受传统PVI。与单纯传统PVI相比,在中位随访12个月期间,腺苷引导的PVI使无心律失常生存率提高了17%[相对风险(RR):1.17;95%置信区间(CI):1.07至1.27;P = 0.014]。接受腺苷引导的PVI的患者与接受传统PVI的患者的透视时间相似[加权平均差(WMD):1.76;95% CI:-5.66至9.17;P = 0.64],尽管手术时间更长(WMD:20.6;95% CI:0.70至40.50;P = 0.042)。
从临床研究的现有数据来看,在接受AF导管消融的患者中,与传统PVI相比,腺苷引导的PVI与无心律失常生存率的提高相关。